This study is being conducted for the treatment of adult and pediatric patients with refractory or recurrent ALL, CLL, as well as diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma with autologous T-lymphocytes transduced with a third generation CAR retroviral vector, aimed at CD19 [214]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.